Gabriela Rosu to Lead Veristat’s Medical Affairs Team

Veristat has recruited Gabriela Rosu, M.D., to its top management team as senior director of Global Medical Affairs.

Rosu has more than 20 years of scientific- and clinical-related experience, having helped planned and executed pivotal activities that led to the approval and commercialization of numerous therapies.

“Dr. Rosu’s fervent commitment to collaboration enhances our ability to make informed decisions, crucially improving patient experiences in clinical trials and ensuring favorable outcomes,” Veristat CEO Patrick Flanagan said. “Her insight into the nuances of oncology therapy development is invaluable, particularly as we continue to focus on optimizing treatment strategies in this area.”

Veristat’s Medical Affairs team is at the forefront of evaluating scientific data to address the increasing complexity of biotherapeutic compounds and diverse patient demographics in clinical trials. The team is instrumental in fostering communication and generating essential evidence to support patient safety and optimize treatment outcomes, especially for those with rare and complex diseases, according to the company.

In her new role, Rosu will oversee the global expansion of the medical and safety/pharmacovigilance teams. Her background includes senior medical affairs positions at leading global CROs, where she supervised medical monitoring for various oncology trials, advised on protocol development, risk mitigation strategies, and strategic development with a focus on patient safety and patient outcomes. Rosu’s experience is particularly notable in immuno-oncology, focusing on managing compound toxicity.

Before transitioning to the CRO industry, Rosu worked as chief medical officer at IMV Inc. and global medical advisor at Novo Nordisk Healthcare, where she led clinical developments in oncology and coagulation disorders, among other responsibilities.

Rosu earned her medical degree in Romania and has maintained active participation in such organizations as the American Society for Clinical Oncology and the European Society for Medical Oncology.

“I am honored to lead as senior director, Global Medical Affairs at Veristat, aligning with the company’s strategic vision to pioneer the development and commercialization of innovative treatments for rare diseases. My dedication to enhancing patient experiences in clinical trials and fostering the development of safe and effective therapies remains unwavering,” Rosu stated. “I look forward to contributing to Veristat’s team and its mission.”

Veristat is the Science-First CRO and consultancy that integrates full service clinical trial execution, regulatory affairs and safety, and strategic advisor services to rapidly advance the development, approval, and commercialization of novel therapies worldwide. With 30 years of experience solving sponsors’ unique and complex clinical, statistical, and regulatory challenges, Veristat’s Science-First experts deliver timely, quality-driven results with solutions that are tailored to the needs of patients, clinical trial sites, regulators, sponsor teams, and key stakeholders.